Treatment Patterns and Survival Outcomes of Non-Small Cell Lung Cancer Patients Initially Diagnosed With Brain Metastases in Real-World Clinical Practice

Xin-Ru Chen1†, Xue Hou1†, Xiao-Xiao Dinglin2†, Yong-Dong Liu3†, Yin Li4, Wei Zheng4, De-Lan Li5, Jing Chen1, Xiao-Liang Wu6, Kai-Cheng Wang1, Shu-Xiang Ma7, Yin-Duo Zeng2 and Li-Kun Chen1*

1 State Key Laboratory of Oncology in South, China Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, 2 Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, 3 Department of Pathology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, 4 Department of Endoscopy, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, 5 Department of Chemotherapy, Zhongshan City People’s Hospital, Zhongshan, China, 6 Department of Oncology, Guizhou Provincial People’s Hospital, Guiyang, China, 7 Department of Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China

Background: This study aimed to comprehensively analyze the characteristics, treatment patterns, and survival outcomes of non-small-cell lung cancer (NSCLC) patients initially diagnosed with brain metastases (BMs) in real-world practice.

Methods: We enrolled NSCLC patients initially diagnosed with BMs between Jan 2004 and Jan 2018 in our institution. Patient demographics, treatment modalities, and survival outcomes were then analyzed. Brain localized treatment (BLT) included early brain radiotherapy (EBR), deferred brain radiotherapy (DBR), and surgery.

Results: A total of 954 patients were identified. Concerning initial treatment, 525 patients (55.0%) received systemic medication (SM)+BLT, 400 patients (41.9%) received SM only, and 29 patients received BLT only (3.0%). SM+BLT cohort was associated with longer median overall survival (mOS) than the SM only and the BLT only cohorts both in epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK)-negative/unknown patients (15.3 months, 95% confidence interval [CI], 14.2–16.4; 11.1 months, 9.0–13.2; 7.0 months, 5.4–8.6; p<0.001) and in EGFR/ALK-positive patients (33.7 months, 28.5–38.9; 22.1 months, 17.8–26.4; 4.0 months, 3.6–4.4; p < 0.001). As for timing of radiotherapy, SM+EBR (14.1 months, 12.7–15.5) was associated with inferior mOS than SM+DBR (19.4 months, 14.2–24.6) in EGFR/ALK-negative/unknown patients. No significant difference was found in EGFR/ALK-positive patients (28.3 months, 19.1–37.5; 33.3 months, 28.1–38.5). Patients in the EGFR/ALK-negative/unknown cohort treated with first-line pemetrexed with platinum (PP) (15.8 months, 14.0–17.6,
INTRODUCTION

Non-small-cell lung cancer (NSCLC) accounts for 80 to 85% of all lung cancers, and more than three-quarters of NSCLC patients present with advanced disease (1, 2). Brain is one of the most common sites of NSCLC metastases, and 30 to 50% of these patients may develop brain metastases (BM) at some point in their lives (3, 4). Besides, 25–30% of patients will experience synchronous BMs (5). Though significant advances have been made in the management of NSCLC in recent years, the prognosis of patients with BMs is still poor.

The management of BMs usually requires a multidisciplinary team that integrates brain localized treatment (BLT), systemic medication (SM), and supportive care. The particular treatment option chosen for BMs mainly depends on the number of BMs, the presence of neurological symptoms, the presence of extracranial metastasis (ECM), the patient’s general health condition, and other factors (6). The current treatment options for managing BMs include surgical resection, whole-brain radiation therapy (WBRT), and stereotactic radiosurgery (SRS), either alone or combined with SM, such as chemotherapy or targeted therapy (7). Thus far, increasing numbers of studies have shown that SM has excellent efficacy for BMs, especially with the emergence of tyrosine kinase inhibitors (TKIs) that target epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK); patients with BMs who harbored these gene mutations thus have opportunities to forego local treatment to the brain in early days (8). Brain radiotherapy is a standard treatment for BMs, and various studies have explored the best sequence in which radiotherapy and SM should be administered in the context of newly diagnosed BMs (9–12). However, the results of these studies have been inconsistent.

Despite the high rate of BMs in NSCLC, patients initially diagnosed with BMs are commonly excluded in several prospective clinical trials, and thus, evidence-based data on the management of these patients are limited. Therefore, we performed a real-world study to comprehensively analyze the characteristics, treatment patterns, and survival outcomes in NSCLC patients with newly diagnosed BMs at a single institution in China.

MATERIALS AND METHODS

Patients and Populations

This study was reviewed and approved by the Guangdong Association Study of Thoracic Oncology (No. A2017-002) and the institutional review board/ethics committee of the participating hospitals, and exception to the requirement of informed consent was approved. We retrospectively identified NSCLC patients who were initially diagnosed with BMs from Jan 2004 to Jan 2018. The inclusion criteria included the following: 1) histologically or cytologically confirmed NSCLC, 2) magnetic resonance imaging (MRI) scans of the brain identified BMs at the time of diagnosis, and 3) available clinical data and follow-up information at Sun Yat-Sen University Cancer Center (SYSUCC). Patients who did not receive further treatment at our center after diagnosis and who did not have follow-up data were excluded. Patient follow-up concluded on October 10, 2019, thereby ensuring a minimum follow-up time of over 1 year for each patient.

The following characteristics were collected for analysis: age, gender, smoking history, Karnofsky Performance Status (KPS) at diagnosis, histology, EGFR and ALK rearrangement, number of BM, neurological symptoms, lungmol-GPA (Graded Prognostic Assessment) index, types of BLT, and name of SM. In our study, BLT included brain radiotherapy (WBRT, SRS, or a combination of the two) and brain surgery (BS). Deferred brain radiotherapy (DBR) was defined as patients who received initial brain radiotherapy after progression on first-line SM but otherwise was considered to be early brain radiotherapy (EBR).
Statistical Analysis
Median overall survival (mOS) was calculated from the date of diagnosis of NSCLC with BMs to the date of death from any cause or the date of the last follow-up. OS was estimated using the Kaplan-Meier method and was compared using the log-rank test. Statistical differences in patient characteristics based on treatment patterns were analyzed using chi-square tests or Fisher’s exact test for categorical measures. To decrease potential treatment selection bias, propensity score matching (PSM) was conducted using a nearest-neighbor algorithm to adjust for demographical and clinical covariates. A two-sided p-value < 0.05 was considered statistically significant. All data were processed with SPSS version 22.0 (SPSS Inc., Chicago, IL, USA).

RESULTS
Baseline Patient Characteristics
In all, 954 patients were eligible for inclusion in our study (Figure 1). Regarding initial treatment approaches, 525 patients (55.0%) received SM+BLT, 400 patients (41.9%) received SM only, and 29 patients received BLT only (3.0%). As for BLT, 346 patients received SM+EBR, 101 (10.6%) received SM+DBR, 78 (8.2%) received SM+BS. Patient characteristics are listed in Table 1. Due to the limited prevalence of testing technology, EGFR and ALK status was available in 619 (64.8%) patients from 2006 and 320 (33.5%) patients from 2012. Among them, 295 patients (41.8%) were EGFR mutant-positive and 27 patients (8.4%) were ALK rearrangement-positive.

The baseline characteristics of 632 patients with negative/unknown EGFR/ALK status and 322 patients with positive EGFR/ALK status grouped according to five treatment patterns are listed in Tables 2, 3. In the EGFR/ALK-negative/unknown cohort, SM only was more likely to be administered to patients with no neurological symptoms (83.6%), those with extracranial metastases (67.2%), and those with a Lung-molGPA of 0–2 (72.7%). SM+EBR was more likely to be administered to patients with >4 brain metastases (51.1%), those presenting with neurological symptoms (64.8%), and those with a lung-molGPA of 0–2 (60.9%). SM+DBR was more likely to be administered to patients without neurological symptoms (77.8%) and to those with a lung-molGPA of 0–2 (66.7%). SM+BS was more likely to be administered to patients with one brain lesion (78.4%), those with symptomatic BMs (84.3%), those without extracranial metastases (86.3%), and those with a favorable prognosis with a lung-molGPA of 2.5–3 (68.6%). Finally, BLT only was more likely to be administered to patients with >4 brain metastases (75.0%), those presenting with neurological symptoms (75.0%), and those with a lung-molGPA of 0–2 (75.0%). In patients with positive EGFR/ALK status, the characteristics of patients who received SM+BS or BLT only were comparable to those with negative/unknown EGFR/ALK status but were somewhat different from the other three patterns. SM only was more likely to be administered to patients with a lung-molGPA of 2.5–4 (92.0%), while SM+EBR was more likely to be administered to patients without neurological symptoms (55.6%) and those with a lung-molGPA of 2.5–4 (87.8%). SM+DBR was more likely to be administered to patients with a lung-molGPA of 2.5–4 (87.8%).
TABLE 1 | Baseline patient characteristics (n = 954).

| Characteristic                      | No. (%) |
|-------------------------------------|---------|
| Age, median (range)                 | 56 (17–89) |
| <65                                 | 780 (81.8) |
| ≥65                                 | 174 (18.2) |
| Gender                              |         |
| Male                                | 598 (62.7) |
| Female                              | 356 (37.3) |
| Smoking status                      |         |
| Never                               | 536 (56.2) |
| Former/current                      | 418 (43.8) |
| Pretreatment KPS                    |         |
| ≤70                                 | 81 (8.5) |
| >70                                 | 873 (91.5) |
| Histology                           |         |
| Adenocarcinoma                      | 839 (88.0) |
| Squamous carcinoma                  | 70 (7.3) |
| Others                              | 45 (4.7) |
| No. of brain metastases             |         |
| 1                                   | 319 (33.4) |
| 2–4                                 | 203 (21.3) |
| >4                                  | 432 (45.3) |
| Neurological symptoms               |         |
| Yes                                 | 306 (32.1) |
| No                                  | 648 (67.9) |
| Extracranial metastases             |         |
| Yes                                 | 559 (58.4) |
| No                                  | 416 (43.6) |
| Gene status                         |         |
| EGFR mutation                       | 295 (31.0) |
| ALK rearrangement                   | 27 (2.8) |
| Wild type                           | 297 (31.1) |
| Unknown                             | 335 (35.1) |
| Lung-molGPA*                        |         |
| 0–1                                 | 92 (9.6) |
| 1.5–2                               | 346 (36.3) |
| 2.5–3                               | 406 (42.6) |
| 3.5–4                               | 110 (11.5) |
| Initial treatment                   |         |
| SM only                             | 400 (41.9) |
| SM+EBR                              | 346 (36.3) |
| SM+DBR                              | 101 (10.6) |
| SM+BS                               | 78 (8.2) |
| BLT only                            | 29 (3.0) |

*ALK, anaplastic lymphoma kinase; AP, pemetrexed with platinum; BS, brain surgery; DBR, deferred brain radiotherapy; DP, docetaxel with platinum; EBR, early brain radiotherapy; EGFR, epidermal growth factor receptor; GP, gemcitabine with platinum; GPA, graded prognostic assessment; KPS, Karnofsky performance status; SM, systemic medication; TKI, tyrosine kinase inhibitor; TP, paclitaxel with platinum.

(86.8%). Consistently, patients who received EBR were more likely to have >4 BMs compared with patients who received DBR either in the negative/unknown cohort (51.1 vs. 34.9%) or in the positive cohort (62.2 vs. 44.8%).

Treatment Patterns and Survival Outcomes

In the entire population, the median follow-up time was 54.8 months (interquartile range, 9.0–33.0). The mOS was 16.5 months (95% confidence intervals [CI], 15.4–17.6). The OS at 1, 3, and 5 years was 64.4, 22.0, and 9.2%, respectively.

The distribution of treatment patterns in 632 EGFR/ALK-negative/unknown patients is shown in Figure 2. More than half the patients received SM+BLT (370, 58.5%) followed by SM (238, 37.7%). Among those treated with SM+BLT, SM+EBR (256/370, 69.2%) was the most common treatment strategy. The mOS of the SM+BLT cohort was significantly longer (15.3 months, 95% CI, 14.2–16.4, p < 0.001, Figure 2) than SM only (11.1 months, 95% CI, 9.0–13.2) and BLT only cohorts (7.0 months, 95% CI, 5.4–8.6). Moreover, patients who received SM+EBR (14.1 months, 95% CI, 12.7–15.5, p < 0.001, Figure 2) had a poor mOS compared with patients who received SM+BS (21.5 months, 95% CI, 11.5–31.5) and SM+DBR (19.4 months, 95% CI, 14.2–24.6).

The distribution of treatment patterns in 322 EGFR/ALK-positive patients is presented in Figure 2. The percentage of the SM only (162, 50.3%) cohort was slightly higher than that of the SM+BLT (155, 48.1%) cohort. Besides, SM+EBR (90/155, 58.1%) remained the most common combined therapy strategy. SM+BLT (33.7 months, 95% CI, 28.5–38.9, p < 0.001, Figure 2) was associated with an improved mOS compared with SM only (22.1 months, 95% CI, 17.8–26.4) and BLT only (4.0 months, 95% CI, 3.6–4.4). Furthermore, the mOS was better in the SM+BS group (62.6 months, 95% CI, 12.4–112.7, p = 0.052, Figure 2) than in the SM+EBR (28.3 months, 95% CI, 19.1–37.5) and SM+DBR (33.3 months, 95% CI, 28.1–38.5) groups, but the difference was not statistically significant.

To clarify the population that would benefit from different combined treatments, we subdivided patients according to the lung-molGPA index. Patients with a more favorable prognosis (lung-molGPA 2.5–4) who received SM+BS had a longer mOS (40.6 months, 95% CI, 28.6–52.6, p < 0.001, Supplementary Figure S1A) than those who were treated with SM+EBR (22.0 months, 95% CI, 18.3–25.7) and those who received SM+DBR (30.3 months, 95% CI, 18.4–42.2); while those with a less favorable prognosis (lung-molGPA 0–2) did not demonstrate improved mOS when treated with SM+BS (15.2 months, 95% CI, 8.1–22.3, Supplementary Figure S1B) compared with those who received SM+EBR (12.7 months, 95% CI, 11.2–14.2) and SM+DBR (19.4 months, 95% CI, 13.4–25.4).

Early Brain Radiotherapy and Deferred Brain Radiotherapy After Prognosis Score Matching

To further investigate the optimal timing of radiotherapy for NSCLC patients initially diagnosed with BMs, we performed PSM to balance the clinical factors between the EBR group and the DBR group. After balancing the covariates, 63 matched patients from the SM+DBR group and 189 matched patients from the SM+EBR group out of the EGFR/ALK-negative/unknown patients were compared and analyzed (1:3 match). The results showed that they were well balanced (Supplementary Table S1). Consistent with the result without PSM, the mOS was also significantly improved in patients who received SM+DBR (19.4 months, 95% CI: 14.2–24.6, p = 0.015, Supplementary Figure S2A) compared with those who received SM+EBR (14.3 months, 95% CI: 12.8–15.8).

Besides, 38 matched EGFR/ALK-positive patients from the SM+DBR and the SM+EBR groups were compared and analyzed (1:1 match) (Supplementary Table S2). No significant difference
### TABLE 2 | Characteristics of the 632 EGFR/ALK-negative/unknown patients.

| Characteristic                  | SM only (n = 238) | SM+EBR (n = 256) | SM+DBR (n = 63) | SM+BS (n = 51) | BLT only (n = 24) | p-value  |
|--------------------------------|------------------|-----------------|----------------|----------------|----------------|----------|
| Age, years                     |                  |                 |                |                |                 |          |
| Median (range)                 | 57 (24–81)       | 56 (24–80)      | 55 (24–77)     | 57 (27–79)     | 57 (30–74)     | 0.213    |
| <65                            | 186 (78.2)       | 209 (81.6)      | 52 (82.5)      | 39 (76.6)      | 15 (62.5)      |          |
| ≥65                            | 52 (21.8)        | 47 (19.4)       | 11 (17.5)      | 12 (23.5)      | 9 (37.5)       |          |
| Gender                         |                  |                 |                |                |                 |          |
| Male                           | 161 (67.6)       | 186 (78.2)      | 42 (66.7)      | 41 (80.4)      | 20 (83.3)      | 0.216    |
| Female                         | 77 (32.4)        | 70 (11.8)       | 20 (33.3)      | 10 (19.6)      | 4 (16.7)       |          |
| Smoking status                 |                  |                 |                |                |                 |          |
| Never                          | 115 (48.3)       | 113 (47.5)      | 35 (56.6)      | 26 (51.0)      | 11 (45.8)      | 0.537    |
| Former/current                 | 123 (51.7)       | 143 (52.5)      | 28 (44.4)      | 25 (49.0)      | 13 (54.2)      |          |
| Pretreatment KPS               |                  |                 |                |                |                 |          |
| >70                            | 211 (88.7)       | 232 (90.6)      | 56 (88.9)      | 45 (88.2)      | 18 (75.0)      | 0.235    |
| ≤70                            | 27 (11.3)        | 24 (9.4)        | 7 (11.1)       | 6 (11.8)       | 6 (25.0)       |          |
| Histology                      |                  |                 |                |                |                 |          |
| Adenocarcinoma                 | 202 (84.9)       | 213 (83.2)      | 57 (90.5)      | 38 (74.5)      | 22 (91.7)      | 0.178    |
| Non-adenocarcinoma             | 36 (15.1)        | 43 (16.8)       | 6 (9.5)        | 13 (25.5)      | 2 (8.3)        |          |
| No. of brain metastases        |                  |                 |                |                |                 |          |
| 1                              | 92 (38.7)        | 69 (27.0)       | 26 (41.3)      | 40 (78.4)      | 4 (16.7)       | <0.001   |
| 2–4                            | 49 (20.6)        | 56 (21.9)       | 15 (23.8)      | 3 (5.9)        | 2 (8.3)        |          |
| >4                             | 97 (40.7)        | 131 (51.1)      | 22 (34.9)      | 8 (15.7)       | 18 (75.0)      |          |
| Neurological symptoms          |                  |                 |                |                |                 |          |
| Yes                            | 39 (16.4)        | 166 (64.8)      | 14 (22.2)      | 43 (84.3)      | 18 (75.0)      | <0.001   |
| No                             | 199 (83.6)       | 90 (35.2)       | 49 (77.8)      | 8 (15.7)       | 6 (25.0)       |          |
| Extracranial metastases        |                  |                 |                |                |                 |          |
| Yes                            | 160 (67.2)       | 129 (50.4)      | 37 (58.7)      | 7 (13.7)       | 10 (41.7)      | <0.001   |
| No                             | 78 (32.8)        | 127 (49.6)      | 26 (41.3)      | 44 (86.3)      | 14 (58.3)      |          |
| Lung-moGPA*                    |                  |                 |                |                |                 |          |
| 0–2                            | 173 (72.7)       | 156 (60.9)      | 42 (66.7)      | 16 (31.4)      | 18 (75.0)      | <0.001   |
| 2.5–3                          | 65 (27.3)        | 100 (39.1)      | 21 (33.3)      | 35 (68.6)      | 6 (25.0)       |          |
| First-line chemotherapy        |                  |                 |                |                |                 |          |
| PP                             | 115 (48.3)       | 92 (35.9)       | 26 (41.3)      | 31 (60.8)      | /              |          |
| TP                             | 81 (34.0)        | 101 (39.5)      | 20 (31.7)      | 13 (25.5)      | /              |          |
| DP                             | 19 (8.0)         | 24 (9.4)        | 3 (4.8)        | 1 (2.0)        | /              |          |
| GP                             | 13 (5.5)         | 23 (9.0)        | 8 (12.7)       | 1 (2.0)        | /              |          |
| Others                         | 10 (4.2)         | 16 (6.2)        | 6 (9.5)        | 5 (9.7)        | /              |          |
| Brain localized therapy        |                  |                 |                |                |                 |          |
| WBRT                           | /                | 183 (71.5)      | 52 (82.5)      | /              | 9 (37.5)       |          |
| SRS                            | /                | 50 (19.5)       | 9 (14.3)       | /              | 3 (12.5)       |          |
| WBRT+SRS                       | /                | 23 (9.0)        | 2 (3.2)        | /              | 1 (4.2)        |          |
| Surgery                        | /                | /               | /              | 51 (100.0)     | 11 (45.8)      |          |

ALK, anaplastic lymphoma kinase; BLT, brain localized treatment; BS, brain surgery; DBR, delayed brain radiotherapy; DP, docetaxel with platinum; EBR, early brain radiotherapy; EGFR, epidermal growth factor receptor; GP, gemcitabine with platinum; GPA, graded prognostic assessment; KPS, Karnofsky performance status; PP, pemetrexed with platinum; SRS, stereotactic radiosurgery; SM, systemic medication; TP, paclitaxel with platinum; WBRT, whole-brain radiotherapy.

*An update of the DS-GPA using molecular markers.

In survival was observed between patients who received SM+DBR (30.8 months, 95% CI: 20.0–41.6, p = 0.846, Supplementary Figure S2B) and those treated with SM+EBR (33.3 months, 95% CI: 28.1–38.5).

**First-Line Systemic Medication and Survival Outcomes**

First-line systemic therapies were administered to 925 (97.0%) patients. For 608 patients with negative/unknown EGFR/ALK status, the most frequently used chemotherapy regimen was pemetrexed with platinum (PP; n = 264 patients, 43.4%, Figure 3). Patients who received PP (15.8 months, 95% CI: 14.0–17.6, p < 0.001, Figure 3) were observed to have a longer mOS than those treated with non-PP regimens (13.1 months, 95% CI: 11.6–14.6).

In the 317 patients with positive EGFR/ALK status, the most frequently used regimens in the first-line setting was EGFR/ALK TKIs (n = 164 patients, 51.7%, Figure 3). Among 157 patients received EGFR TKIs, all patients were treated with first-generation EGFR TKI, such as gefitinib, erlotinib, and icotinib, and no patients received osimertinib, the third generation EGFR TKI, which was granted accelerated approval by the China Food and Drug Administration (CFDA) in March 2017 to treat T790M-positive NSCLC patients as second-line therapy. For seven patients who received ALK TKIs, all were treated with crizotinib as first-line regimen. No significant difference was observed among patients who received EGFR/ALK TKIs (29.5 months, 95% CI: 21.1–37.9, p = 0.140, Figure 3), PP (27.2 months, 95% CI: 21.6–32.8) and non-PP regimens (25.0 months, 95% CI: 16.0–34.0).
TABLE 3 | Characteristics of the 322 EGFR/ALK-positive patients.

| Characteristic                  | SM only (n = 162) No. (%) | SM+EBR (n = 90) No. (%) | SM+DBR (n = 38) No. (%) | SM+BS (n = 27) No. (%) | BLT only (n = 5) No. (%) | p-value |
|---------------------------------|--------------------------|------------------------|-------------------------|------------------------|-------------------------|---------|
| Age, years                      |                          |                        |                         |                        |                         |         |
| Median (range)                  | 53 (26–89)               | 54 (17–78)             | 53 (33–67)              | 61 (29–74)             | 50 (49–70)              | 0.106   |
| <65                             | 138 (85.2)               | 79 (87.8)              | 37 (97.4)               | 21 (77.8)              | 4 (80.0)                |         |
| ≥65                             | 24 (14.8)                | 11 (12.2)              | 1 (2.6)                 | 6 (22.2)               | 1 (20.0)                |         |
| Gender                          |                          |                        |                         |                        |                         |         |
| Male                            | 70 (43.2)                | 45 (50.0)              | 21 (55.3)               | 10 (37.0)              | 1 (20.0)                | 0.345   |
| Female                          | 92 (56.8)                | 45 (50.0)              | 17 (44.7)               | 17 (63.0)              | 4 (80.0)                |         |
| Smoking status                  |                          |                        |                         |                        |                         |         |
| Never                           | 125 (77.2)               | 57 (63.3)              | 25 (65.8)               | 24 (88.9)              | 5 (100.0)               | 0.019   |
| Former/current                  | 37 (22.8)                | 33 (36.7)              | 13 (34.2)               | 3 (1.1)                | 0 (0)                   |         |
| Pretreatment KPS                |                          |                        |                         |                        |                         |         |
| >70                             | 155 (95.7)               | 88 (97.8)              | 38 (100.0)              | 26 (96.3)              | 4 (80.0)                | 0.212   |
| ≤70                             | 7 (4.3)                  | 2 (2.2)                | 0 (0)                   | 1 (3.7)                | 1 (20.0)                |         |
| Histology                       |                          |                        |                         |                        |                         |         |
| Adenocarcinoma                  | 156 (96.3)               | 86 (95.6)              | 37 (97.4)               | 24 (88.9)              | 4 (80.0)                | 0.166   |
| Non-adenocarcinoma              | 6 (3.7)                  | 4 (4.4)                | 1 (2.6)                 | 3 (1.1)                | 1 (20.0)                |         |
| No. of brain metastases         |                          |                        |                         |                        |                         |         |
| 1                               | 48 (29.6)                | 18 (20.0)              | 7 (18.4)                | 14 (51.9)              | 1 (20.0)                | 0.003   |
| 2–4                             | 41 (25.3)                | 16 (17.8)              | 14 (36.8)               | 7 (25.0)               | 0 (0)                   |         |
| >4                              | 73 (45.1)                | 56 (62.2)              | 17 (44.8)               | 6 (22.1)               | 4 (80.0)                |         |
| Neurological symptoms           |                          |                        |                         |                        |                         |         |
| No                              | 25 (15.4)                | 40 (44.4)              | 9 (23.7)                | 24 (88.9)              | 4 (80.0)                | <0.001  |
| Yes                             | 137 (84.6)               | 50 (55.6)              | 29 (76.3)               | 3 (11.1)               | 1 (20.0)                |         |
| Extracranial metastases        |                          |                        |                         |                        |                         |         |
| Yes                             | 106 (65.4)               | 52 (57.8)              | 28 (73.7)               | 20 (74.1)              | 2 (40.0)                | 0.225   |
| No                              | 56 (34.6)                | 38 (42.2)              | 10 (26.3)               | 7 (25.9)               | 3 (60.0)                |         |
| Gene status                     |                          |                        |                         |                        |                         |         |
| EGFR mutation                   | 154 (95.1)               | 82 (91.1)              | 34 (89.5)               | 22 (81.5)              | 3 (60.0)                | 0.015   |
| ALK rearrangement               | 8 (4.9)                  | 8 (8.9)                | 4 (10.5)                | 5 (18.5)               | 2 (40.0)                |         |
| Lung-molGPA*                    |                          |                        |                         |                        |                         |         |
| 0–2                             | 13 (8.0)                 | 11 (12.2)              | 5 (13.2)                | 2 (8.0)                | 2 (40.0)                | 0.165   |
| 2.5–4                           | 149 (92.0)               | 79 (87.8)              | 33 (86.8)               | 25 (92.0)              | 3 (60.0)                |         |
| First-line chemotherapy         |                          |                        |                         |                        |                         |         |
| EGFR TKIs                       | 79 (48.8)                | 43 (47.8)              | 21 (55.3)               | 15 (55.6)              | /                       |         |
| ALK TKIs                        | 2 (1.2)                  | 2 (2.2)                | 2 (5.3)                 | 1 (3.7)                | /                       |         |
| PP                              | 72 (44.4)                | 27 (30.0)              | 14 (36.8)               | 10 (37.0)              | /                       |         |
| TP                              | 8 (4.0)                  | 10 (11.1)              | 1 (2.6)                 | 0 (0)                  | /                       |         |
| Others                          | 1 (0.6)                  | 8 (4.9)                | 0 (0)                   | 1 (3.7)                | /                       |         |
| Brain localized therapy         |                          |                        |                         |                        |                         |         |
| WBRT                            | /                        | 64 (71.1)              | 34 (89.4)               | /                      | 3 (60.0)                |         |
| SRS                             | /                        | 21 (23.3)              | 2 (5.3)                 | /                      | 0 (0)                   |         |
| WBRT+SRS                        | /                        | 5 (5.6)                | 2 (5.3)                 | /                      | 0 (0)                   |         |
| Surgery                         | /                        | /                      | 27 (100.0)              | 2 (40.0)               |                         |         |

ALK, anaplastic lymphoma kinase; BLT, brain localized treatment; BS, brain surgery; DBR, deferred brain radiotherapy; EBR, early brain radiotherapy; EGFR, epidermal growth factor receptor; GPA, graded prognostic assessment; KPS, Karnofsky performance status; PP, pemetrexed with platinum; SRS, stereotactic radiosurgery; SM, systemic medication; TKI, tyrosine kinase inhibitor; TP, paclitaxel with platinum; WBRT, whole-brain radiotherapy.

*An update of the DS-GPA using molecular markers.

Besides, our study consisted of 88% of adenocarcinoma and 12% of non-adenocarcinoma, the detailed first-line treatment regimens subdivided by histology were shown in Supplementary Table S3.

DISCUSSION

The results of this study provide real-world experience in advanced NSCLC patients initially diagnosed with BMs, including treatment choices and survival outcomes, and help to provide an understanding of how the different treatment strategies that are currently available should be sequenced during the course of therapy. To our knowledge, this is the largest retrospective analysis of the literature on NSCLC patients initially diagnosed with BMs in China.

Our study indicated that SM combined with BLT was a better treatment strategy than SM or BLT alone regardless of EGFR and ALK status. Previous studies have described the poor ability of drugs to penetrate the blood-brain barrier (BBB), and considerable efforts have been made in developing novel agents that have better BBB penetration than earlier drugs (13, 14). Although newly developed drugs such as pemetrexed and EGFR/ALK TKIs have shown certain intracranial activity, many patients will experience progression of intracranial disease due to a lack of more effective drugs (15–18). Brain radiotherapy...
remains an important treatment option due to its simplicity of delivery and its ability to treat intracranial disease.

Though the QUARTZ study reported that compared with optimal supportive care, WBRT provided little additional clinical benefit for patients with BMs, approximately 40% of patients in this cohort had a KPS less than 70, and more than 50% of patients had an uncontrolled primary lung tumor (19). Additionally, enrolled patients were not eligible for SRS and surgery, which...
essentially caused selection bias in that patients with the poorest prognosis received WBRT. Comparatively, in our study, enrolled patients were newly diagnosed with BMs with good performance status, and several patients were also treated with SRS as well as with surgery. Therefore, brain localized therapies should not be omitted, as they might improve the survival and quality of life of some selected patients.

In our study, the impact of SM+BS on patient survival was most pronounced in patients with a more favorable prognosis (lung-molGPA 2.5–4), which can be explained by the nature of oligometastatic disease. More patients in this subgroup have neurological symptoms, 1–4 BMs and do not have extracranial metastasis (ECM). In addition, a subset of these patients also received aggressive treatment for primary lung lesions. Mounting evidence has suggested that aggressive treatment for oligometastatic NSCLC is needed, especially since the appropriate use of multidisciplinary methods may lead to a curable disease state and increased long-term survival (20). Therefore, for patients with oligometastatic BMs, BS could be used as an aggressive treatment option, while SM controls ECM and potentially controls intracranial micrometastatic disease.

Brain radiotherapy (WBRT and SRS) is the most widely used therapeutic approach in patients with BMs. In clinical practice, many clinicians may choose brain radiotherapy to alleviate neurological symptoms or as salvage radiotherapy after failure of standard treatment. However, the optimal timing of brain radiotherapy for NSCLC patients with BM remains controversial. Moreover, treatment strategies for BMs and extracranial lesions in NSCLC patients with wild-type genes or unknown genetics and those with oncogenic-driven NSCLC vary widely. In the current study, for patients with negative/unknown EGFR/ALK status, the proportion of patients who received SM+EBR was similar to those received SM but four times as high as those who received SM+DBR; it was also found that more patients in the SM+EBR group had neurological symptoms. This suggests that initial treatment with EBR was preferred by many practitioners for managing symptomatic BMs. However, patients who received DBR were more likely to have improved mOS relative to those who received EBR, and this result was unchanged after PSM. Consistent with a
randomized phase III study conducted by Robinet, the results showed that the timing (early or delayed) of WBRT did not influence the survival of NSCLC patients with BMs who were treated with concurrent chemotherapy (21). Other prospective studies have also reported similar results and indicated that brain radiotherapy, especially early WBRT, may impair patients’ neurocognitive function (16, 22, 23).

For patients with positive EGFR/ALK status, the percentage of patients who received SM+EBR was also higher than the percentage of patients who received SM+DBR. With a sharp decline in the proportion of patients in the SM+EBR group compared with those in the EGFR/ALK-negative/unknown group, more clinicians chose SM alone as an initial treatment modality, which might be related to the higher efficacy of EGFR or ALK TKIs compared with traditionally cytotoxic drugs. Growing evidence suggests that EGFR or ALK TKIs, especially next-generation TKIs, might allow patients with BMs to forego local treatment to the brain, as they have already shown important activity for intracranial disease (24, 25). Until now, randomized studies on the optimal timing of brain radiotherapy in cases of oncogenic-driven NSCLC with BMs are scarce, and most studies were retrospective in nature. Results from three meta-analyses reported a similar survival after front-line EGFR TKI with brain RT (generally WBRT) and EGFR TKI alone (26–28). However, findings from another retrospective study conducted by Magnuson et al. showed a significantly worse survival in EGFR-mutated patients who received delayed brain radiotherapy, regardless of whether they underwent SRS or WBRT (29). Our study showed that patients who received SM+EBR failed to exhibit improved survival compared with those treated with SM+DBR, and the result was identical after PSM. But we should notice that most patients in these two groups were initially treated with WBRT, the sample size of patients who received SRS was too small. Therefore, whether the optimal timing of brain radiotherapy for this group of patients. EGFR/ALK-negative/unknown patients, especially for those with adenocarcinoma, can significantly benefit from chemotheraphy consisting of pemetrexed plus platinum. In the future, prospective clinical trials and multidisciplinary participation will be required to clarify the optimal treatment pattern for NSCLC patients initially diagnosed with BMs.

Our study had some limitations. Firstly, this retrospective study had inherent biases. We excluded patients with missing medical records and those who were lost to follow-up, both of which could lead to selection bias. Secondly, due to the small sample size in some radiotherapy subgroups, we were unable to further compare the efficacies of different radiotherapy methods. Thirdly, this study was based on data from a top cancer center in China, which may not represent the real-world experiences of hospitals at other levels.

The current study provides a unique set of real-world data that adds to the current understanding of treatment decisions and survival outcomes in NSCLC patients initially diagnosed with BMs. Our study confirmed that patients who initially received SM+BLT are associated with superior mOS than those who were treated with SM only and BLT only. Besides, DBR might be a better timing of radiotherapy for this group of patients. EGFR/ALK-negative/unknown patients, especially for those with adenocarcinoma, can significantly benefit from chemotheraphy consisting of pemetrexed plus platinum. In the future, prospective clinical trials and multidisciplinary participation will be required to clarify the optimal treatment pattern for NSCLC patients initially diagnosed with BMs.

**DATA AVAILABILITY STATEMENT**

All datasets presented in this study are included in the article/Supplementary Material.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Guangdong Association Study of Thoracic Oncology (No. A2017-002) and the institutional review board/ethics committee of the participating hospitals. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

**AUTHOR CONTRIBUTIONS**

X-RC, XH, X-XD, and Y-DL had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. X-RC, XH, YL, WZ, D-LL, and JC contributed to the study design. X-LW, K-CW, S-XM, and X-RC, XH, X-XD, and Y-DL had full access to all of the data in the study in accordance with the national legislation and the institutional requirements.

**FUNDING**

This work was supported by the National Natural Science Foundation of China (Grant No. 81572270), Sun Yat-Sen
SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.581729/full#supplementary-material
25. Lin JJ, Jiang GY, Joshipura N, Ackil J, Digumarthy SR, Rincon SP, et al. Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases. *J Thoracic Oncol* (2019) 14(4):683–90. doi: 10.1016/j.jtho.2018.12.002

26. Soon YY, Leong CN, Koh WY, Tham IW. EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis. *Radiother Oncol J Eur Soc Ther Radiol Oncol* (2015) 114(2):167–72. doi: 10.1016/j.radonc.2014.12.011

27. Zheng H, Liu QX, Hou B, Zhou D, Li JM, Lu X, et al. Clinical outcomes of WBRT plus EGFR-TKIs versus WBRT or TKIs alone for the treatment of cerebral metastatic NSCLC patients: a meta-analysis. *Oncotarget* (2017) 8(34):57356–64. doi: 10.18632/oncotarget.19054

28. Dong K, Liang W, Zhao S, Guo M, He Q, Li C, et al. EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases. *Trans Lung Cancer Res* (2019) 8(3):268–79. doi: 10.21037/tlcr.2019.06.12

29. Yang JJ, Zhou C, Huang Y, Feng J, Lu S, Song Y, et al. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial. *Lancet Respir Med* (2017) 5(9):707–16. doi: 10.1016/s2213-2600(17)30262-x

30. Yu X, Fan Y. Effect of pemetrexed on brain metastases from nonsmall cell lung cancer with wild-type and unknown EGFR status. *Medicine* (2019) 98(3): e14110. doi: 10.1097/md.00000000000014110

31. Moro-Sibilot D, Smit E, de Castro Carpeno J, Lesniewski-Kmak K, Aerts JG, Villatoro R, et al. Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study. *Lung Cancer (Amsterdam Netherlands)* (2015) 90(3):427–32. doi: 10.1016/j.lungcan.2015.11.011

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2020 Chen, Hou, Dinglin, Liu, Li, Zheng, Li, Chen, Wu, Ma, Zeng and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*